Jaguar Animal Health, which is developing an animal formulation of its parent's approved diarrhea treatment, announced terms for its IPO on Friday.
The San Francisco, CA-based company plans to raise $22 million by offering 3.2 million shares at a price of $7 per share. At that price, Jaguar would command a fully diluted market value of $62 million.
It originally planned to raise to raise $40 million at a diluted market cap of $86 million in November, but postponed its offering.
In its latest filing, Jaguar replaced underwriters BMO Capital Markets, Guggenheim Securities and Roth Capital Partners with Aegis Capital, CRT Capital and Feltl and Company. It also updated its financial results for the fiscal year ended December 31, 2014.
Jaguar Animal Health, which was founded in 2013, plans to list on the NASDAQ under the symbol JAGX. Aegis Capital is the sole bookrunner on the deal. IPO timing was not disclosed.
